Tuesday, May 15, 2018


Surface Pharmaceuticals, Inc. Announces $20 Million Series A ...

PR Newswire (press release)-3 hours ago
The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or
Post a Comment